VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

ECTRIMS 2022 | Safety and efficacy of aHSCT for MS

Riccardo Saccardi, MD, Careggi University Hospital, Florence, Italy, outlines the existing evidence showing that autologous hematopoietic stem cell transplantation (aHSCT) is a safe and effective treatment for multiple sclerosis (MS). Data from the last 20 years shows that aHSCT is very effective in MS patients, but it is an invasive procedure with significant safety risks. However, the advances in transplant technology have improved its safety. Regarding conditioning regimens for aHSCT, the optimal one has yet to be defined, with experiences varying across centers. Future prospective studies will provide further insights, but most likely, the best conditioning regimen will be the one that is tailored to the clinical characteristics of the patient. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.